摘要
目的:对照分析信迪利单抗联合培美曲塞+顺铂(AP)治疗晚期肺腺癌患者的疗效和不良反应发生情况,为临床应用提供参考。方法:选取2019年3月—2022年11月中国人民解放军联勤保障部队第九六二医院收治的33例经病理学或细胞学明确诊断为晚期肺腺癌的患者作为研究对象,随机将其分为研究组17例和对照组16例。研究组患者接受信迪利单抗联合AP方案化疗,对照组患者接受AP方案化疗。比较两组患者治疗后近期疗效、远期疗效和不良反应发生情况。结果:研究组患者客观缓解率(ORR)和疾病控制率(DCR)均高于对照组患者,差异有统计学意义(P<0.05)。治疗后,两组患者癌胚抗原(CEA)、糖类抗原125(CA125)水平均下降,且研究组患者CEA、CA125水平均低于对照组患者,差异有统计学意义(t=-2.088、-2.060,P<0.05)。研究组患者高血压发生率高于对照组患者,差异有统计学意义(P<0.05);两组患者发热、疲劳、恶心呕吐等其他不良反应发生率比较,差异无统计学意义(P>0.05)。结论:信迪利单抗联合AP治疗晚期肺腺癌患者较单用AP治疗疗效更好,并未明显增加不良反应。
Objective: To study the efficacy and adverse reactions of sintillimab combined with pemetrexed and cisplatin in the treatment of advanced lung adenocarcinoma, so as to provide reference for clinical application. Methods: 33 patients with advanced lung adenocarcinoma confirmed by pathology or cytology admitted to the hospital from March 2019 to November 2022were selected as the study objects. They were randomly divided into 17 cases in study group and 16 cases in control group. The study group received sintillimab combined with AP regimen, and the control group received AP regimen. The short-term and longterm efficacy, and the incidence of adverse reactions were compared between the two groups. Results: ORR and DCR in the study group were higher than the control group, with statistically significant difference(P<0.05). After treatment, serum CEA and CA125 levels in study group and control group decreased,and the decrease in the study group was higher than that in the control group, with statistically significant difference(t=-2.088,-2.060;P<0.05). After treatment,the incidence of hypertension in study group was higher than that in control group, with statistically significant difference(P<0.05). But there was no statistically significant difference in gastrointestinal reaction, bone marrow suppression, fever, fatigue, liver and kidney function,albuminuria,myalgia,oral ulcer and thyroid function(P>0.05). Conclusion: Sintillimab combined with AP regimen has better efficacy than AP regimen in the treatment of advanced lung adenocarcinoma, with no significant increase in adverse reactions,which is worthy of clinical application.
作者
韩惠娟
马静霞
徐畅
单思维
Han Huijuan;Ma Jingxia;Xu Chang(Department of Oncology,962 Hospital,Harbin,Heilongjiang,150000,China)
出处
《黑龙江医学》
2024年第10期1204-1206,1210,共4页
Heilongjiang Medical Journal
关键词
晚期肺腺癌
信迪利单抗
培美曲塞
顺铂
Advanced lung adenocarcinoma
Sintillimab
Pemetrexed
Cisplatin
